← Back to Nuqta Atlas
Editorially curated · qa-noor-qatar-beginngs
NOOR-QATAR Genome-based Newborn Screening Program
Large-scale newborn genome screening research tailored to Qatar, linking early genomic risk detection with confirmatory pathways and treatments.
01 / Project overview
What the record establishes.
- Geographic scope
- National ambition; Sidra Medicine is the first international BeginNGS site
- Project type
- newborn genome screening research program
- Research domain
- newborn genomics, rare disease, and preventive medicine
- Years
- 2025–
- Lifecycle status
- active early implementation
- Status basis
- Sidra announced the BeginNGS collaboration on 20 August 2025 and stated that it builds on the successful launch of NOOR-QATAR.
- Status evidence date
- 2025-08-20
- Scale
- BeginNGS currently screens 511 severe childhood diseases and aims for 1,000 diseases in 10 countries by 2030; Qatar-specific enrollment has not been published.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Sidra Medicine
- Partner organizations
- Rady Children's Institute for Genomic Medicine · BeginNGS Consortium
- Organism / population
- Newborns in Qatar
03 / Data and access
What exists and how it can be reached.
Data types
- newborn whole-genome sequencing
- screening algorithms
- clinical confirmation
- polygenic risk
Data access
Clinical/research program; no public participant-level data release.
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Named national-scale newborn-genomics research initiative with an international screening protocol.
Editorial note
Distinct from HMC's Q-Chip newborn-screening pilot: NOOR-QATAR uses genome sequencing and Sidra/BeginNGS infrastructure.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0